Adlai Nortye Price to Free Cash Flow Ratio 2025-2024 | ANL

Adlai Nortye price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as

Adlai Nortye Price to Free Cash Flow Ratio 2025-2024 | ANL

Adlai Nortye price to free cash flow ratio from 2025 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.8B
Vertex Pharmaceuticals (VRTX)$117.5B
Regeneron Pharmaceuticals (REGN)$111.6B
Bristol Myers Squibb (BMY)$109.4B
Gilead Sciences (GILD)$105.3B
CSL (CSLLY)$95.7B
GSK (GSK)$80.5B
Alnylam Pharmaceuticals (ALNY)$34.4B
Argenex SE (ARGX)$31.7B
BioNTech SE (BNTX)$29.2B
Biogen (BIIB)$27B
BeiGene (BGNE)$23.9B
Moderna (MRNA)$23.1B
Illumina (ILMN)$22.5B
Genmab (GMAB)$15.5B
BioMarin Pharmaceutical (BMRN)$13.2B
Incyte (INCY)$13B
Exact Sciences (EXAS)$12.6B
Vaxcyte (PCVX)$12.4B
Insmed (INSM)$12.4B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.5B
QIAGEN (QGEN)$9.9B
Bio-Rad Laboratories (BIO.B)$9.3B
Legend Biotech (LEGN)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.3B
Revolution Medicines (RVMD)$7.9B
Intra-Cellular Therapies (ITCI)$7.7B
Repligen (RGEN)$7.7B